142 related articles for article (PubMed ID: 35217362)
21. T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity.
Sailer N; Fetzer I; Salvermoser M; Braun M; Brechtefeld D; Krendl C; Geiger C; Mutze K; Noessner E; Schendel DJ; Bürdek M; Wilde S; Sommermeyer D
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454906
[TBL] [Abstract][Full Text] [Related]
22. The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy.
Tang X; Li Q; Zhu Y; Zheng D; Dai J; Ni W; Wei J; Xue Y; Chen K; Hou W; Zhang C; Feng X; Liang Y
Am J Transl Res; 2015; 7(3):460-73. PubMed ID: 26045887
[TBL] [Abstract][Full Text] [Related]
23. Tethering IL2 to Its Receptor IL2Rβ Enhances Antitumor Activity and Expansion of Natural Killer NK92 Cells.
Jounaidi Y; Cotten JF; Miller KW; Forman SA
Cancer Res; 2017 Nov; 77(21):5938-5951. PubMed ID: 28916655
[TBL] [Abstract][Full Text] [Related]
24. Novaferon gene modification promotes NK92 cell anti-tumor activity.
Zhang W; Yu B; Meng Q; Pu L; Liu B; Li F
Int Immunopharmacol; 2023 Sep; 122():110613. PubMed ID: 37421776
[TBL] [Abstract][Full Text] [Related]
25. PKCι regulates the expression of PDL1 through multiple pathways to modulate immune suppression of pancreatic cancer cells.
Zhang H; Zhu Y; Wang J; Weng S; Zuo F; Li C; Zhu T
Cell Signal; 2021 Oct; 86():110115. PubMed ID: 34375670
[TBL] [Abstract][Full Text] [Related]
26. PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells.
Guo Y; Feng X; Jiang Y; Shi X; Xing X; Liu X; Li N; Fadeel B; Zheng C
Oncotarget; 2016 Jul; 7(30):48360-48374. PubMed ID: 27356741
[TBL] [Abstract][Full Text] [Related]
27. Chimeric antigen receptor modified T cell (CAR-T) co-expressed with ICOSL-41BB promote CAR-T proliferation and tumor rejection.
Hu W; Huang X; Huang X; Chen W; Hao L; Chen Z
Biomed Pharmacother; 2019 Oct; 118():109333. PubMed ID: 31545280
[TBL] [Abstract][Full Text] [Related]
28. Influence of reverse signaling via membrane TNF-alpha on cytotoxicity of NK92 cells.
Yu M; Shi W; Zhang J; Niu L; Chen Q; Yan D; Liu T; Jing W; Jiang X; Wei F; Yin B; Zhang W; Li Q; Li Z
Eur J Cell Biol; 2009 Mar; 88(3):181-91. PubMed ID: 18950896
[TBL] [Abstract][Full Text] [Related]
29. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
30. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D.
Wang Z; Guo L; Song Y; Zhang Y; Lin D; Hu B; Mei Y; Sandikin D; Liu H
Cancer Immunol Immunother; 2017 Apr; 66(4):537-548. PubMed ID: 28184969
[TBL] [Abstract][Full Text] [Related]
31. Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo.
Pegram HJ; Jackson JT; Smyth MJ; Kershaw MH; Darcy PK
J Immunol; 2008 Sep; 181(5):3449-55. PubMed ID: 18714017
[TBL] [Abstract][Full Text] [Related]
32. Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy.
Zhang J; Sun R; Wei H; Zhang J; Tian Z
Haematologica; 2004 Mar; 89(3):338-47. PubMed ID: 15020274
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA.
Kundu K; Ghosh S; Sarkar R; Edri A; Brusilovsky M; Gershoni-Yahalom O; Yossef R; Shemesh A; Soria JC; Lazar V; Joshua BZ; Campbell KS; Elkabets M; Porgador A
Cancer Immunol Res; 2019 Jul; 7(7):1120-1134. PubMed ID: 31164357
[TBL] [Abstract][Full Text] [Related]
34. A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function.
Hoogi S; Eisenberg V; Mayer S; Shamul A; Barliya T; Cohen CJ
J Immunother Cancer; 2019 Sep; 7(1):243. PubMed ID: 31500665
[TBL] [Abstract][Full Text] [Related]
35. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of therapeutic effects of natural killer (NK) cell-based immunotherapy in mice using in vivo apoptosis bioimaging with a caspase-3 sensor.
Lee HW; Singh TD; Lee SW; Ha JH; Rehemtulla A; Ahn BC; Jeon YH; Lee J
FASEB J; 2014 Jul; 28(7):2932-41. PubMed ID: 24736413
[TBL] [Abstract][Full Text] [Related]
37. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
[TBL] [Abstract][Full Text] [Related]
38. Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy.
Klapdor R; Wang S; Hacker U; Büning H; Morgan M; Dörk T; Hillemanns P; Schambach A
Hum Gene Ther; 2017 Oct; 28(10):886-896. PubMed ID: 28836469
[TBL] [Abstract][Full Text] [Related]
39. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
[TBL] [Abstract][Full Text] [Related]
40. [Killing effect of Robo1 targeted Chimeric Antigen Receptor modified NK92 cells against glioma and neuroblastoma cells].
Qu Y; Bi JZ
Zhonghua Yi Xue Za Zhi; 2018 Mar; 98(11):860-866. PubMed ID: 29609271
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]